Loading patent…
AssigneesLes Laboratoires Servier, Institut National De La Sante Et De La Recherche Medicale (Inserm), Centre National de la Recherche Scientifique (CNRS)
InventorsJulie Pannequin, Laure Boudier, Dominique Joubert, Frédéric Hollande
Estimating the term…
The present disclosure is directed to progastrin monoclonal antibodies, fragments thereof, compositions comprising progastrin monoclonal antibodies, and methods of making and using progastrin monoclonal antibodies and compositions thereof. The present disclosure is directed to methods of treating colorectal cancer with progastrin monoclonal antibodies and compositions comprising progastrin monoclonal antibodies or fragments thereof. The present disclosure is further directed to methods comprising detection of progastrin, including methods of diagnosing colorectal cancer and methods of monitoring efficacy of anti-cancer therapy in subjects suffering from colorectal cancer.
A monoclonal antibody that specifically binds human progastrin (hPG).
A method of treating colorectal cancer comprising administering to a subject an amount of a humanized neutralizing anti-hPG monoclonal antibody effective to treat the colorectal cancer.
A method of inhibiting proliferation of colorectal tumor cells, comprising exposing the colorectal tumor cells to a neutralizing anti-hPG monoclonal antibody.
A method of inhibiting a progastrin-dependent signal transduction cascade in a cell, comprising exposing cells that secretes hPG to an amount of a neutralizing anti-hPG monoclonal antibody effective to inhibit progastrin-dependent signal transduction.
Dependencies are inferred from the claim text.